RxDoctor Payments Data

Jamie Peatrowsky, PA

Physician Assistant · Sacramento, CANPI 1821564360

Payments from drug & device makers

$1,548in general payments, 2019–2025

Across 19 payments — averaging $81.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Coloplast$170
  • Astellas Pharma US Inc$89
  • 180 Medical, Inc.$75
  • Bayer$57
  • AbbVie$56
  • plus $56 from 2 others

What the payments were for

  • Travel & lodging$66743%
  • Food & beverage$79151%
  • Education$896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC8$1,045
Coloplast1$170
Astellas Pharma US Inc1$89
180 Medical, Inc.3$75
Bayer1$57
AbbVie(2 entities)3$56
Boston Scientific1$47
Intuitive Surgical1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,548 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$35,125
Medicare patients
239
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$8,224
Alfuzosin Hcl ErAlfuzosin Hcl168$3,380
Tamsulosin Hcl260$2,970
Finasteride94$1,759
Solifenacin Succinate50$1,631
Desmopressin Acetate22$1,424
Cefdinir45$1,249
Testosterone Cypionate29$1,226
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$1,124
Tolterodine Tartrate ErTolterodine Tartrate13$1,092
Fesoterodine Fumarate ErFesoterodine Fumarate14$987
Oxybutynin Chloride112$822
Silodosin13$649
Oxybutynin Chloride ErOxybutynin Chloride37$630
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim125$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$89$8,22415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →